이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Cassava Sciences 미래 성장
Future 기준 확인 2/6
Cassava Sciences은 연간 수입과 매출이 각각 17.5%와 32.6% 증가할 것으로 예상되고 EPS는 연간 23.3%만큼 증가할 것으로 예상됩니다.
주요 정보
17.5%
수익 성장률
23.3%
EPS 성장률
Pharmaceuticals 수익 성장 | 27.6% |
매출 성장률 | 32.6% |
향후 자기자본 수익률 | n/a |
애널리스트 커버리지 | Low |
마지막 업데이트 | 17 May 2024 |
최근 미래 성장 업데이트
Recent updates
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28Cassava Sciences Stock: Here We Go Again
Dec 21Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
Dec 02Cassava Sciences Gets Underway Putting Simufilam To The Test
Nov 24Cassava Sciences: Data Rules!
Nov 17Cassava Sciences' Hypothesis Raises Doubts
Nov 08Cassava Sciences Stock: Massive Potential Marred By Controversy
Nov 01Cassava Sciences: Welcome To The Casino
Oct 25Has Cassava Sciences Put Out The Fire For Now?
Sep 28Cassava Sciences: Medical History In The Making
Sep 21Cassava Sciences: One Doubtful Drug For One Doubtful Indication
Sep 15We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth
Sep 14More On Cassava Sciences' Controversy
Sep 04Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor
Aug 26수익 및 매출 성장 예측
날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
---|---|---|---|---|---|
12/31/2026 | N/A | -67 | N/A | N/A | 1 |
12/31/2025 | 100 | 18 | N/A | N/A | 2 |
12/31/2024 | N/A | -37 | N/A | N/A | 2 |
3/31/2024 | N/A | -48 | -88 | -88 | N/A |
12/31/2023 | N/A | -97 | -82 | -82 | N/A |
9/30/2023 | N/A | -95 | -81 | -81 | N/A |
6/30/2023 | N/A | -90 | -77 | -76 | N/A |
3/31/2023 | N/A | -83 | -70 | -67 | N/A |
12/31/2022 | N/A | -76 | -80 | -78 | N/A |
9/30/2022 | N/A | -71 | -67 | -64 | N/A |
6/30/2022 | N/A | -61 | -81 | -57 | N/A |
3/31/2022 | N/A | -46 | -74 | -51 | N/A |
12/31/2021 | N/A | -32 | -52 | -30 | N/A |
9/30/2021 | N/A | -21 | -45 | -23 | N/A |
6/30/2021 | N/A | -13 | -11 | -11 | N/A |
3/31/2021 | N/A | -9 | -6 | -6 | N/A |
12/31/2020 | N/A | -6 | -5 | -5 | N/A |
9/30/2020 | N/A | -5 | -5 | -5 | N/A |
6/30/2020 | N/A | -4 | -3 | -3 | N/A |
3/31/2020 | N/A | -4 | -3 | -3 | N/A |
12/31/2019 | N/A | -5 | -3 | -3 | N/A |
9/30/2019 | N/A | -4 | -3 | -2 | N/A |
6/30/2019 | N/A | -4 | -3 | -3 | N/A |
3/31/2019 | N/A | -6 | -4 | -4 | N/A |
12/31/2018 | N/A | -7 | -5 | -5 | N/A |
9/30/2018 | N/A | -8 | -6 | -6 | N/A |
6/30/2018 | N/A | -10 | -6 | -6 | N/A |
3/31/2018 | N/A | -11 | -8 | -8 | N/A |
12/31/2017 | N/A | -12 | N/A | -8 | N/A |
9/30/2017 | N/A | -12 | N/A | -10 | N/A |
6/30/2017 | N/A | -13 | N/A | -10 | N/A |
3/31/2017 | N/A | -12 | N/A | -11 | N/A |
12/31/2016 | N/A | -15 | N/A | -12 | N/A |
9/30/2016 | N/A | -17 | N/A | -13 | N/A |
6/30/2016 | N/A | -17 | N/A | -12 | N/A |
3/31/2016 | N/A | -17 | N/A | -11 | N/A |
12/31/2015 | N/A | -14 | N/A | -9 | N/A |
9/30/2015 | N/A | -12 | N/A | -8 | N/A |
6/30/2015 | N/A | -12 | N/A | -7 | N/A |
3/31/2015 | N/A | -12 | N/A | -8 | N/A |
12/31/2014 | N/A | -12 | N/A | -10 | N/A |
9/30/2014 | 35 | 23 | N/A | -8 | N/A |
6/30/2014 | 37 | 26 | N/A | -9 | N/A |
3/31/2014 | 39 | 29 | N/A | -8 | N/A |
12/31/2013 | 41 | 32 | N/A | -7 | N/A |
9/30/2013 | 8 | -3 | N/A | -7 | N/A |
6/30/2013 | 9 | -4 | N/A | -7 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: SAVA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: SAVA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: SAVA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: SAVA 의 수익(연간 32.6% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).
고성장 수익: SAVA 의 수익(연간 32.6% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: SAVA 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.